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DOES PAIN IN ONE KNEE AFFECT MEASUREMENT OF ISOMETRIC
MUSCLE STRENGTH IN THE CONTRALATERAL LIMB? – DATA FROM
THE OSTEOARTHRITIS INITIATIVE (OAI)
E. Steidle y, W. Wirth y, A. Ruhrdorfer y, S. Cotofana y, N.A. Segal z,
F. Eckstein y. y Inst. of Anatomy, Paracelsus Med. Univ., Salzburg, Austria;
zDept.s of Orthopaedics & Rehabilitation, Univ. of Iowa, Iowa City, IA,
United States
Purpose: Muscle strength is an important prerequisite for adequate
lower limb function and quality of life. Lack of thigh muscle strength is
thought to play a potential role in the onset and progression of symp-
tomatic knee OA, and is currently recommended for treatment of knee
OA by the OARSI therapeutic guidelines. Force generated by the lower
limb can be measured objectively to test unilateral muscle strength,
whereas most other functional performance tests rely on both limbs.
However, it is currently unclear to what extent measurement of knee
extensor and ﬂexor strength is independent of the pain status of the
contralateral knee. The purpose of this study therefore was to deter-
mine whether pain in one knee affects the measurement of isometric
muscle strength in the contralateral limb.
Methods: We used data from the Osteoarthritis Initiative (OAI), to
explore whether isometric thigh muscle strength differs between the
asymptomatic (pain-free) knee of participants with a non-acceptable
symptom status in the contralateral knee (cases), and matched knees of
participants without pain in either knee (controls). Of the 4796 OAI
participants, 3078 had bilateral measurement of isometric muscle
strength, full demographic information available at 2-year follow-up,
and did not have end-stage radiographic (KLG4) knee OA. Of these, 312
fulﬁlled our case deﬁnition of unilateral pain: a) one knee with a
numerical rating scale (NRS) pain intensity value 4 (i.e. greater than
the patient acceptable symptoms state [PASS]) and either frequent pain
(Sx2) or infrequent pain (Sx1) during in the past 12 months; b) the
contralateral knee with an NRS intensity value of 0-1, either no pain
(Sx0) or infrequent pain (Sx1) during in the past 12 months, and a
WOMAC score of 0–1. 1027 of the 3078 participants fulﬁlled the control
deﬁnition of bilateral pain-free knees, i.e. both knees had an NRS
intensity value of 0–1, either no (or infrequent) pain during in the past
12 months (Sx0 or 1), and a WOMAC score of 0–1. Of the 312 partic-
ipants with unilateral pain, 224 could be matched to a control with the
same sex and race (White/African American), and with similar age
(5y), body height (5cm), BMI (3kg/m2) and radiographic knee OA
status (KLG 0/1 or 2/3). The maximal force [N] obtained from three
isometric measurements of extensor and ﬂexor muscle strength (Good
strength chair) at the shank during 60 knee ﬂexionwas used. The pain-
free limb in each participant with contralateral painwas comparedwith
the matched limb from a bilaterally pain-free participant.
Results: Cases with unilateral painwere 58% female, 63.9 8.9 (mean
SD) years old, and had a BMI of 28.1  4.2 kg/m2. The maximum
extensor strength of pain-free knees of participants with contralateral
knee pain (cases) was, on average, 5.2% lower (p ¼ 0.04) than that of
matched bilaterally pain-free controls (Table 1). The maximum ﬂexor
strength also was signiﬁcantly lower (7.7%, p ¼ 0.02) in cases than in
controls, whereas the difference in the physical activity score of the
elderly (PASE: 7.5%, p ¼ 0.12) did not attain statistical signiﬁcance
(Table 1). As a reference, the extensor strength in the painful limbs of
the cases (312  112 N) was signiﬁcantly (p ¼ 0.00001) lower than that
of the pain-free limb in the same participant (5.9% ¼ 19.8 N [95%
CI:28.5;11.2]), and the same applied for ﬂexor strength (123  52.8
N: difference 3.9% ¼ 5.0 N [95%CI:9.0;1.0]; p ¼ 0.01).Table 1
Muscle strength in pain-free limbs in unilaterally cases vs. bilaterally controls
Case (Mean  SD) Control (Mea
Extensor strength [N] 333  108 351  146
Flexor strength [N] 128  52.4 139  74.1
PASE-score (0–361) 148  69.2 158  83.0
Age [years] 63.9  8.9 63.8  8.8
BMI [kg/m2] 28.1  4.2 28.1  4.2Conclusions: The results suggest that isometric strength measurement
in a limb with an asymptomatic knee is not independent of the pain
status of the contralateral knee. Effects from the contralateral knee may
be conveyed by central nervous system inhibition, or from a reduction
in training status and general physical activity. Although the effect
appears relatively small for the given conditions (i.e. the contra-lateral
knee having an NRS4), it is almost as large as the difference between
painful and the painless limbs in cases with unilateral non-acceptable
knee pain.
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MECHANICAL PAIN THRESHOLD PREDICTS RESPONSE TO INTRA-
ARTICULAR STEROID THERAPY IN SYMPTOMATIC KNEE
OSTEOARTHRITIS
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Purpose: Quantitative Sensory Testing (QST) is a non-invasive test
battery that assesses sensory perception of pressure, mechanical and
vibration stimuli. Pressure pain thresholds assessed at a pain free
control site prior to surgery have been shown to predict pain levels one
year after total knee replacement in patients with knee osteoarthritis
(OA). However, to our knowledge there are no data looking at associa-
tions between QST measures and response to pharmacological inter-
ventions. The aim of this study was to determine whether, in patients
with symptomatic knee OA, baseline QST measures predicted response
to treatment with intra-articular steroid therapy and whether response
was associated with change in any of the QST measures.
Methods: 32men andwomenwith symptomatic kneeOAparticipating in
an uncontrolled open label clinical trial of intra-articular steroid therapy
completed QST assessments at the injected and contralateral knees at
baseline prior to intra-articular injection of depomedrone (80 mg) with
repeat assessments after an interval of between 5 and 15 days following
the injection. Subjectswerealsoasked tocomplete thepainsubscaleof the
Knee Injury andOsteoarthritis Outcome Score (0–100 scale,worst to best)
at baseline and at the follow-up assessment. The QST assessments per-
formedat bothknees included:mechanical detection threshold (0.25–512
mN von Frey ﬁlaments), mechanical pain threshold and mechanical pain
sensitivity (8–512 mN punctate probes), dynamic mechanical allodynia
(brush and cotton bud), vibration detection (64 Hz tuning fork), pressure
pain (0–10kg/cm2 algometer) and wind-up (256 mN punctate probe).
Patients also had a tender point examination (0–18 sites). Subjects were
characterised as treatment responders or treatment non-responders at
the followupvisit using theOARSI-OMERACTcriteria.Wilcoxon rank-sum
tests were used to determine differences between responders and non-
responders in QST measures at baseline and in changes in the QST
measures following intervention.Withinperson changes inQSTmeasures
were assessed using the Wilcoxon matched-pairs signed-rank test.
Results: 11 men and 21 women (mean age 62.8 years, SD 10.2 years)
with symptomatic knee OA underwent QST assessments at the injected
and contralateral knees. Twenty one (65.6%) participants were classiﬁed
as treatment responders at follow-up. Compared to non-responders,
treatment responders had signiﬁcantly lower mean baseline mechan-
ical pain thresholds at the injected knee (73.4, SD ¼ 74.6 vs 147.6, SD ¼
112.6; p ¼ 0.022) with values for the control knee also approaching
signiﬁcance (78.5, SD ¼ 64.2 vs 123.5, SD ¼ 68.6; p ¼ 0.054), indicating
higher sensitivity to mechanical pain among the responders. None of
the other baseline QST assessments, however, differed by respondern  SD) Difference (95% Conﬁd. Int.) Paired t test
-18.2 (-35.7/-0.7) p ¼ 0.04
-10.7 (-19.9/-1.6) p ¼ 0.02
-11.8 (-24.6/1.0) p ¼ 0.12
0.1 (-0.1/0.3) p ¼ 0.30
0.0 (-0.1/0.1) p ¼ 0.77
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measures following intervention. Among responders, there was a small
decrease in within person change in mechanical detection threshold
(25.1, SD ¼ 69.1), indicating increased sensitivity, while in non-res-
ponders there was a small increase indicating decreased sensitivity
(22.4, SD ¼ 61.8) with a signiﬁcant difference between responders and
non-responders (p ¼ 0.04). There was no other signiﬁcant within per-
son change in any of the QST measures by responder status.
Conclusions: In this small interventional study, patients with higher
sensitivity to mechanical pain were more likely to respond to intra-
articular steroid therapy.
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CHRONIC PAIN IN PATIENTS WITH THE HYPERMOBILITY TYPE OF
EHLERS–DANLOS SYNDROME: EVIDENCE FOR GENERALIZED
HYPERALGESIA
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Purpose: The Ehlers–Danlos Syndrome (EDS) is one the most prevalent
heritable connective tissue disorders. Generalized severe joint hyper-
mobility, which is frequently associated with joint dislocations, chronic
joint and limb pain, and premature osteoarthritis, are the dominant
clinical manifestations of the hypermobility type of EDS (EDS-HT).
Chronic widespread pain is highly present in this patient group, but up
to now, evidence for generalized hyperalgesia is lacking. Several studies
in chronic pain disorders examined whether central hyperexcitability
could be existent by using algometry.
Therefore, the primary objective of the study was to investigate
whether pressure pain thresholds (PPTs) at both symptomatic and
asymptomatic body areas differ in EDS-HT patients compared to
healthy subjects. In addition, we examined the type of chronic pain
EDS-HT patients experience.
Methods: Twenty-three women with EDS-HT and 23 gender- and age-
matched healthy controls participated. All subjects marked on Margolis
Pain Diagram where they felt pain lasting longer than 24 hours in the
past 4 weeks. Then, they completed several questionnaires assessing
pain cognitions (Pain Catastrophizing Scale, Pain Vigilance and
Awareness Questionnaire, Hospital Anxiety and Depression Scale),
fatigue (Checklist Individual Strength subscale fatigue), disability
(Health Assessment Questionnaire), and general health status (Short
Form Health Survey-36), in order to take the possible inﬂuence of these
factors on PPTs into account. Patients also completed the Pain Detect
Questionnaire regarding the severity, course, quality and nature of the
pain they experienced. Thereupon, a blinded researcher assessed PPTs
at 14 body locations on the trunk and extremities. The pressure was
gradually increased at a rate of 1 kg/s until the subject indicated that the
pain level has been reached. The threshold was determined as the mean
of the 2 last values out of the 3 consecutive measurements. This method
has been found to be efﬁcient and reliable in the exploration of path-
ophysiological mechanisms involved in pain. PPTs were compared for
the 2 complete groups. In addition, PPTs of patients and controls who
did not report pain in a respective zone were compared.
Results: The EDS-HT patient group demonstrated signiﬁcantly lower
PPTs compared to the control group for all zones. The mean (SD) PPT
was 2.9 (1.62) kg/cm2 in the EDS-HT patients and 5.2 (1.88) kg/cm2 in
the controls (P < 0.001). Also at asymptomatic (pain-free) zones, EDS-
HT patients systematically showed signiﬁcantly lower pain thresholds
compared to the healthy subjects. No confounding factors responsible
for the observed differences could be revealed.
According to the Margolis Pain Diagram, EDS-HT patients experienced
pain on an average of 31% (17.8) of their body surface, compared to 1%
(2.4) in the control subjects. Furthermore, approximately 40% of the
patients presented with a nociceptive pain pattern, whereas in about
50% a predominantly neuropathic pain component was likely present.
Conclusion: This study shows that several forms of pain coexist in
EDS-HT which are likely the result of different pain-triggering mech-
anisms. The widespread pain lacking local distinction together with
the lower PPTs in body zones outside and remote to the symptomaticzone provide evidence for the existence of generalized secondary
hyperalgesia in patients with EDS-HT, which may represent the
involvement of a sensitized central nervous system as an important
mechanism in the chronic pain problems of this challenging patient
group.
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PREDICTIVE VALIDITY OF THE PAIN BELIEF SCREENING INSTRUMENT
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Purpose: To assess the predictive validity of the Pain Belief Screening
Instrument (PBSI) for predicting clinically meaningful change in
patient-perceived pain following conservative non-drug therapy; and
to establish a cut-off value that distinguishes patients at risk of not
achieving meaningful pain reduction following intervention (exercise
therapy and/or manual therapy).
Methods: We used data from 308 patients in two randomized clinical
trials (RCTs) of people with hip or knee osteoarthritis (OA), at baseline
and 6-month follow-up. Pain was assessed using a numeric pain rating
scale (NPRS) in one RCT and a visual analog scale (VAS) in the second
RCT. From recent literature we considered the minimum clinically
important difference (MCID) to be 2 points on a 0–10 scale. To deter-
mine the association between baseline PBSI and clinically important
change in pain at 6-month follow-up we used a three-phase approach:
ﬁrst using development data set, then an establishment dataset and
subsequently a validation dataset, we estimated area under the curve
(AUC) and parsimonious cut-point, using receiver operating character-
istics (ROC) analyses, and predicted change in pain using linear
regression.
Results: The data sets included 90 patients with hip OA in the devel-
opment set, 116 patients with knee OA in the establishment set and 102
patients with hip OA in the validation set, The cut point on the PBSI (0–
40 scale) was 27, 27 and 26 in the development, establishment and
validation sets, respectively. The AUC for PBSI was .70, .70 and .65 in the
development, establishment and validation sets, respectively. Regres-
sion of change in patient-perceived pain scores was statistically sig-
niﬁcant in all data sets (p < 0.05), but not clinically signiﬁcant, with the
cut-point associated with a difference in pain change of 1.3 points in the
development set, 1.2 points in the establishment set, and 1.3 points in
the validation set.
Conclusions: The PBSI demonstrated some predictive validity for esti-
mating 6-month pain responsiveness to therapy, however the mean
magnitude of difference in pain, between patients scoring above versus
below these ROC-derived cut-points, did not reach the minimum clin-
ically important difference, and the AUC values indicated onlymoderate
accuracy. Despite a high level of consistency among the three datasets,
the lack of clinically important difference in pain outcome suggests that
this information is unlikely to be useful for targeting therapy, however
it may be useful for statistically adjusting for variables associated with
outcome in clinical research.
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ENDOGENOUS PAIN MODULATION IN THE EHLERS–DANLOS
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I. De Wandele, Jr., L. Hermans, Jr., L. Rombaut, Sr., M. Meeus, Sr.,
G. Brusselmans, Sr., F. Malfait, Sr., A. De Paepe, Sr., P. Calders, Sr.. Ghent
Univ., Ghent, Belgium
Purpose: The Ehlers–Danlos Syndrome (EDS) is the most prevalent
heritable connective tissue disorder. More than 90% of individuals are
classiﬁed as having the hypermobility type (EDS-HT). Patients typically
demonstrate generalized severe joint hypermobility, which is fre-
quently associated with recurrent joint dislocations and premature
osteoarthritis. Although pain is the number one complaint in EDS-HT,
causing severe disability in daily life, the underlying pain mechanisms
and the nature of pain are unknown. Therefore, this study aims to assess
the nature of pain (nociceptive / neuropathic / dysfunctional pain) and
the endogenous pain modulation in EDS-HT.
